Polatuzumab vedotin

Generic name: Polatuzumab Vedotin
Brand names: Polivy
Dosage form: intravenous powder for injection (140 mg; 30 mg)
Drug class: Miscellaneous antineoplastics

Usage of Polatuzumab vedotin

Polatuzumab vedotin is used to treat diffuse large B-cell lymphoma after at least two other cancer treatments did not work or have stopped working.

Polatuzumab vedotin is given in combination with Bendamustine (Bendeka, Treanda) and a medicine that contains rituximab (Rituxan).

Polatuzumab vedotin may also be used for purposes not listed in this medication guide.

Polatuzumab vedotin side effects

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Polatuzumab vedotin may cause a serious brain infection that can lead to disability or death. Call your doctor right away if you have problems with speech, thought, vision, or muscle movement. These symptoms may start gradually and get worse quickly.

Some side effects may occur during the injection. Tell your caregiver if you feel feverish, chilled, itchy, light-headed, or have wheezing, chest tightness, or trouble breathing within 24 hours after the injection.

Polatuzumab vedotin may cause serious side effects. Call your doctor at once if you have:

easy bruising or bleeding (nosebleeds, bleeding gums);

muscle weakness;

cough with mucus, chest pain, feeling short of breath;

pale skin, cold hands and feet, feeling light-headed;

nerve problems--numbness, tingling, pain, burning sensation in your hands or feet, weakness, trouble walking;

signs of infection--fever, chills, night sweats, cough, mouth sores, swollen glands, shallow breathing, pain or burning when you urinate, weight loss;

signs of shingles--flu-like symptoms, tingly or painful blistering rash on one side of your body;

liver problems--loss of appetite, stomach pain (upper right side), dark urine, jaundice (yellowing of the skin or eyes); or

signs of tumor cell breakdown--confusion, weakness, muscle cramps, nausea, vomiting, fast or slow heart rate, decreased urination, tingling in your hands and feet or around your mouth.

Common side effects of polatuzumab vedotin may include:

fever, cough, tiredness, or other signs of infection;

nerve problems; or

diarrhea, loss of appetite.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Polatuzumab vedotin

Tell your doctor if you have ever had:

liver disease; or

nerve problems (neuropathy) in your hands and feet.

Polatuzumab vedotin can harm an unborn baby or cause birth defects if the mother or the father is using polatuzumab vedotin.

If you are a woman, you may need to have a negative pregnancy test before starting this treatment. Do not use polatuzumab vedotin if you are pregnant. Use effective birth control to prevent pregnancy while you are using this medicine and for at least 3 months after your last dose.

If you are a man, use effective birth control if your sex partner is able to get pregnant. Keep using birth control for at least 5 months after your last dose.

Tell your doctor right away if a pregnancy occurs while either the mother or the father is using polatuzumab vedotin.

This medicine may affect fertility (ability to have children) in men. However, it is important to use birth control to prevent pregnancy because polatuzumab vedotin can harm an unborn baby.

Do not breastfeed while using this medicine, and for at least 2 months after your last dose.

Relate drugs

How to use Polatuzumab vedotin

Usual Adult Dose for Lymphoma:

1.8 mg/kg IV every 21 days for 6 cycles in combination with bendamustine and rituximab; administer this drug, bendamustine, and rituximab in any order on Day 1 of each cycle-The recommended dose of bendamustine is 90 mg/m2/day IV on Days 1 and 2 of each cycle-The recommended dose of rituximab is 375 mg/m2 IV on Day 1 of each cycle.Comments:-Premedicate with an antihistamine and antipyretic at least 30 minutes prior to therapy.-Administer the initial dose of this drug over 90 minutes. -Monitor patients for infusion-related reactions during the infusion and for a minimum of 90 minutes following completion of the initial dose. If the previous infusion was well tolerated, the subsequent dose may be administered as a 30-minute infusion and patients should be monitored during the infusion and for at least 30 minutes after completion of the infusion.-If a dose of this drug is missed, administer as soon as possible. Adjust the schedule of administration to maintain a 21-day interval between doses.Use: In combination with bendamustine and a rituximab product for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least 2 prior therapies

Warnings

Polatuzumab vedotin affects your immune system. You may get infections more easily, even serious or fatal infections. Call your doctor if you have a fever, chills, cough, mouth sores, unusual bleeding or bruising, burning when you urinate, or problems with speech, thought, or muscle movement.

What other drugs will affect Polatuzumab vedotin

Sometimes it is not safe to use certain medications at the same time. Some drugs can affect your blood levels of other drugs you take, which may increase side effects or make the medications less effective.

Polatuzumab vedotin can harm your liver, especially if you also use certain medicines for infections, tuberculosis, depression, birth control, hormone replacement, high cholesterol, heart problems, high blood pressure, seizures, pain, or arthritis (including Tylenol, Advil, Motrin, or Aleve).

Other drugs may affect polatuzumab vedotin, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.